Trial Profile

Phase 2 Study Of Single-Agent PF-03084014 In Patients With Advanced Triple-Negative Breast Cancer With Or Without Genomic Alterations In Notch Receptors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 07 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nirogacestat (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors Pfizer

Most Recent Events

05 Oct 2021 This trial has been completed in Spain, according to European Clinical Trials Database record. (2016-01-26)
23 Feb 2018 This trial has been completed in Italy, according to European Clinical Trials Database.
02 Nov 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com